NK cells in the tumor microenvironment

Critical Reviews in Oncogenesis

Volumn 19, Issue 1-2, 2014, Pages 91-105

  Larsen, Stine K ^a,b   Gao, Yanhua ^c   Basse, Per H ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b Mental Health Services CPH   (Denmark)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anti tumor effect; IL 2; Infiltration; Natural killer cells; Prognosis; Tumor microenvironment; Virus

Indexed keywords

INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CELL ACTIVATION; CELL DENSITY; CELLULAR DISTRIBUTION; CIRCULATING TUMOR CELL; CYTOKINE RESPONSE; CYTOTOXICITY; HUMAN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL; TUMOR MICROENVIRONMENT;

HUMANS; KILLER CELLS, NATURAL; NEOPLASMS; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 84899651527     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.2014011142     Document Type: Article

References (78)

1. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer. 1975 Aug 15;16(2):216-229.
2. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J I. 1975 Feb;5(2):112-117.
3. Brunda MJ, Rosenbaum D, Stern L. Inhibition of experimentally-induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases. Int J Cancer. 1984 Sep 15;34(3):421-426.
4. Gorelik E, Herberman RB. Susceptibility of various strains of mice to urethan-induced lung tumors and depressed natural killer cell activity. J Nat Cancer Inst. 1981 Dec;67(6):1317-1322.
5. Gorelik E, Kedar E, Sredni B, Herberman R. In vivo anti-tumor effects of local adoptive transfer of mouse and human cultured lymphoid cells. Int J Cancer. 1981 Aug 15;28(2):157-164.
6. Hinuma S, Naruo K, Ootsu K, Houkan T, Shiho O, Tsukamoto K. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells. Immunology. 1987 Feb;60(2):173-179.
7. Basse P, Hokland P, Heron I, Hokland M. Fate of tumor cells injected into left ventricle of heart in BALB/c mice: role of natural killer cells. J Nat Cancer Inst. 1988 Jul 6;80(9):657-665.
8. Yang Q, Goding SR, Hokland ME, Basse PH. Antitumor activity of NK cells. Immunol Res. 2006;36(1-3):13-25.
9. Vaquer S, Jorda J, Lopezdela Osa E, Alvarezdelos Heros J, Lopez-Garcia N, Alvarezde Mon M. Clinical implications of natural killer (NK) cytotoxicity in patients with squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 1990 Jan;36(1):90-92.
10. Dennert G, Landon C, Lord EM, Bahler DW, Frelinger JG. Lysis of a lung carcinoma by poly I:C-induced natural killer cells is independent of the expression of class I histocompatibility antigens. J Immunol. 1988 Apr 1;140(7):2472-5.
11. Edwards BS, Borden EC, Smith-Zaremba K. Divergence in activation by poly I:C of human natural killer and killer cells. Cancer Immunol Immunother. 1982;13(3):158-163.
12. Fresa KL, Korngold R, Murasko DM. Induction of natural killer cell activity of thoracic duct lymphocytes by polyinosinic-polycytidylic acid (poly(I:C)) or interferon. Cell Immunol. 1985 Apr 1;91(2):336-343.
13. Kiuchi Y. Strain diference in mouse natural killer activity augmented by mouse interferon and poly I.C. Jikken dobutsu Exper Anim. 1986 Jul;35(3):239-244.
14. Murata A. [Te effect of activated pulmonary natural killer (NK) cells by poly I:C on the established pulmonary metastasis]. Nihon Ika Daigaku Zasshi. 1989 Aug;56(4):383-391.
15. Tokunaga T, Yamamoto S, Namba K. A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth. Jap J Cancer Res. 1988 Jun;79(6):682-686.
16. Won SJ, Lin MT. Alpha-methyl-p-tyrosine reduces poly I:C-induced augmenting inter-feron production and splenic natural killer cell activity in mice. Pharmacology. 1993 Jun;46(6):332-340.
17. Markovic SN, Murasko DM. Anesthesia inhibits poly I:C induced stimulation of natural kill-er cell cytotoxicity in mice. Clin Immunol Immunopathol. 1990 Aug;56(2):202-209.
18. Beilin B, Martin FC, Shavit Y, Gale RP, Liebeskind JC. Suppression of natural killer cell activity by high-dose narcotic anesthesia in rats. Brain, Behav Immun. 1989 Jun;3(2):129-137.
19. Grifth CD, Rees RC, Platts A, Jermy A, Peel J, Rogers K. Te nature of enhanced natural killer lymphocyte cytotoxicity during anesthesia and surgery in patients with benign disease and cancer. Ann Surg. 1984 Dec;200(6):753-758.
20. Hsueh CM, Lorden JF, Hiramoto RN, Ghanta VK. Acquisition of enhanced natural killer cell activity under anesthesia. Life Sciences. 1992;50(26):2067-2074.
21. Katzav S, Shapiro J, Segal S, Feldman M. General anesthesia during excision of a mouse tumor accelerates postsurgical growth of metas-tases by suppression of natural killer cell activity. Israel J Med Sci. 1986 May;22(5):339-345.
22. Markovic SN, Murasko DM. Inhibition of induction of natural killer activity in mice by general anesthesia (Avertin): role of inter-feron. Clin Immunol Immunopathol. 1991 Aug;60(2):181-189.
23. Schantz SP, Romsdahl MM, Babcock GF, Nishioka K, Goepfert H. Te effect of surgery on natural killer cell activity in head and neck cancer patients: in vitro reversal of a postopera-tively suppressed immunosurveillance system. Laryngoscope. 1985 May;95(5):588-594.
24. Tartter PI, Martinelli G, Steinberg B, Barron D. Changes in peripheral T-cell subsets and natural-killer cytotoxicity in relation to colorec-tal cancer surgery. Cancer Detect Prevent. 1986;9(3-4):359-64.
25. Tonnesen E, Mickley H, Grunnet N. Natural killer cell activity during premedication, anaesthesia and surgery. Acta Anaesthesiol Scand. 1983 Jun;27(3):238-241.
26. Tai LH, de Souza CT, Belanger S, Ly L, Alkayyal AA, Zhang J, Rintoul JL, Ananth AA, Lam T, Breitcach CJ, Falls TJ, Kirn DH, Bell JC, Makrigiannis AP, Auer RA. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res. 2013 Jan 1;73(1):97-107.
27. Tai LH, Zhang J, Scott KJ, de Souza CT, Alkayyal AA, Ananth AA, Sahi S, Adair RA, Mahmoud AB, Sad S, Bell JC, Makrigiannis AP, Melcher AA, Auer RC. Perioperative infuenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells. Clin Cancer Res. 2013 Sep 15;19(18):5104-5115.
28. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Digestive Surgery. 2003;20(5):445-451.
29. Barlozzari T, Reynolds CW, Herberman RB. In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J Immunol. 1983 Aug;131(2):1024-1027.
30. Hanna N. Role of natural killer cells in control of cancer metastasis. Cancer Metastasis Revs. 1982;1(1):45-64.
31. Introna M, Mantovani A. Natural killer cells in human solid tumors. Cancer Metastasis Revs. 1983;2(4):337-350.
32. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH. NKG2D-defcient mice are deffective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008 Apr;28(4):571-580.
33. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M. Te prognostic signifcance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997 Jun 15;79(12):2320-2328.
34. Villegas FR, Coca S, Villarrubia VG, Jiménez R, Chillón MJ, Jareño J, Zuil M, Callol L. Prognostic signifcance of tumor infltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002 Jan;35(1):23-28.
35. Vaquero J, Zurita M, Coca S. Clinical behavior in metastatic brain disease is not infuenced by the immunological defense mediated by CD57 NK-Cells. Int J Surg Oncol. 2012;2012:834852.
36. Smyth MJ, Kelly JM, Baxter AG, Korner H, Sedgwick JD. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exper Med. 1998 Nov 2;188(9):1611-1619.
37. Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado J P. Toll-like receptor 3 expressing tumor parenchyma and infltrating natural killer cells in hepatocellular carcinoma patients. J Nat Cancer Inst. 2012 Dec 5;104(23):1796-807.
38. Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. In Vivo. 1999 May-Jun;13(3):199-204.
39. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 2008 Oct 15;68(20): 8437-8445.
40. Basse P, Goldfarb RH. Localization of immune effector cells to tumor metastases. Immunol Ser. 1994;61:149-158.
41. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exper Med. 1991 Aug 1;174(2):479-488.
42. Basse PH. Tissue distribution and tumor localization of effector cells in adoptive immuno-therapy of cancer. APMIS Suppl. 1995;55:1-28.
43. Basse PH, Nannmark U, Johansson BR, Herberman RB, Goldfarb RH. Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. J Nat Cancer Inst. 1991 Jul 3;83(13):944-950.
44. Vujanovic NL, Basse P, Herberman RB, Whiteside TL. Antitumor functions of natural killer cells and control of metastases. Methods. 1996 Apr;9(2):394-408.
45. Yang Q, Goding S, Hagenaars M, Carlos T, Albertsson P, Kuppen P, Nannmark U, Hokland ME, Basse PH. Morphological appearance, content of extracellular matrix and vascular density of lung metastases predicts permissiveness to infltration by adoptively transferred natural killer and T cells. Cancer Immunol Immunother. 2006 Jun;55(6): 699-707.
46. Basse PH, Goldfarb RH, Herberman RB, Hokland ME. Accumulation of adoptively transferred A-NK cells in murine metastases: kinetics and role of interleukin-2. In Vivo. 1994 Jan-Feb;8(1):17-24.
47. Yang Q, Hokland ME, Bryant JL, Zhang Y, Nannmark U, Watkins SC, Goldfarb RH, Herberman RB, Basse PH. Tumor-localization by adoptively transferred, interleukin-2-acti-vated NK cells leads to destruction of well-established lung metastases. Int J Cancer. 2003 Jul 1;105(4):512-519.
48. Katre NV, Knauf MJ, Laird WJ. Chemical modifcation of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc Nat Acad Sci U S A. 1987 Mar;84(6):1487-1491.
49. Zimmerman RJ, Aukerman SL, Katre NV, Winkelhake JL, Young JD. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modifed interleukin 2 in murine tumor models. Cancer Res. 1989 Dec 1;49(23):6521-6528.
50. Meyers FJ, Paradise C, Scudder SA, Goodman G, Konrad M. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2. Clin Pharmacol Ter. 1991 Mar;49(3):307-313.
51. Yang JC, Schwarz SL, Perry-Lalley DM, Rosenberg SA. Murine studies using polyethylene glycol-modifed recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer. Lymphokine Cytokine Res. 1991 Dec;10(6):475-480.
52. Cotran RS, Pober JS, Gimbrone MA Jr, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT. Endothelial activation during interleukin 2 immunotherapy. A possible mechan-ism for the vascular leak syndrome. J Immunol. 1988 Mar 15;140(6):1883-1888.
53. Pockaj BA, Yang JC, Lotze MT, Lange JR, Spencer WF, Steinberg SM, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J Soc Biol Ter. 1994 Jan;15(1):22-28.
54. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Nat Acad Sci U S A. 1999 Mar 30;96(7):3957-3962.
55. Samlowski WE, Kondapaneni M, Tarkar S, McGregor JR, Laubach VE, Salvemini D. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. J Immunother. 2011 Jun;34(5):419-427.
56. Nagashima S, Mailliard R, Kashii Y, Reichert TE, Herberman RB, Robbins P, Whiteside TL. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood. 1998 May 15;91(10):3850-3861.
57. Goding S, Yang Q, Mi Z, Robbins PD, Basse PH. Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells. Cancer Gene Terapy. 2007 May;14(5):441-450.
58. Goding SR, Yang Q, Knudsen KB, Potter DM, Basse PH. Cytokine gene therapy using adenovirally transduced, tumor-seeking activated natural killer cells. Human Gene Terapy. 2007 Aug;18(8):701-711.
59. Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002 Nov 15;100(10):3633-3638.
60. Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exper Med. 2004 Oct 4;200(7):825-834.
61. Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL, Butterfeld LH. Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood. 2010 Jul 29;116(4):575-583.
62. Katakam AK, Yang Q, Goding S, Kumar P, Basse PH. 270. Te RheoSwitch[reg] therapeutic system precisely regulates IL-2 expression in melanoma cells and supports survival of NK cells at the tumor site. Mol Ter. 2006 05//print;13(S1):S103.
63. Bergman I, Whitaker-Dowling P, Gao Y, Grifn JA. Preferential targeting of vesicular stomatitis virus to breast cancer cells. Virology. 2004 Dec 5;330(1):24-33.
64. Gao Y, Whitaker-Dowling P, Watkins SC, Grifn JA, Bergman I. Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line. J Virol. 2006 Sep;80(17): 8603-12.
65. Bergman I, Grifn JA, Gao Y, Whitaker-Dowling P. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int J Cancer. 2007 Jul 15;121(2):425-30.
66. Gao Y, Whitaker-Dowling P, Griffin JA, Barmada MA, Bergman I. Recombinant vesicular stomatitis virus targeted to Her2/ neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors. Cancer Gene Terapy. 2009 Jan;16(1):44-52.
67. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011 Oct 1;17(19):6287-6297.
68. Mule JJ, Yang J, Shu S, Rosenberg SA. Te anti-tumor efcacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol. 1986 May 15;136(10):3899-3909.
69. Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Powell DJ Jr. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011 Jul 1;71(13):4617-4627.
70. Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepa-tectomy. Cancer. 1998 Jul 1;83(1):58-63.
71. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000 Feb 1;88(3):577-583.
72. Takanami I, Takeuchi K, Giga M. Te prognostic value of natural killer cell infltration in resected pulmonary adenocarcinoma. J Toracic Cardiovascular Surg. 2001 Jun;121(6):1058-63.
73. Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol. 2001 Feb;96(2):574-578.
74. Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V, Prentice HG. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Brit J Haematol. 2002 Jun;117(4):821-827.
75. Cozar JM, Canton J, Tallada M, Concha A, Cabrera T, Garrido F, Ruiz-Cabello Osuna F. Analysis of NK cells and chemokine receptors in tumor infltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother. 2005 Sep;54(9):858-866.
76. Donskov F. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. Danish Med Bull. 2007 Nov;54(4):249-265.
77. Hsia JY, Chen JT, Chen CY, Hsu CP, Miaw J, Huang YS, Yang CY. Prognostic signifcance of intratumoral natural killer cells in primary resected esophageal squamous cell carcinoma. Chang Gung Med J. 2005 May;28(5): 335-340.
78. Sznurkowski JJ, Zawrocki A, Biernat W. Subtypes of cytotoxic lymphocytes and natural killer cells infltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma. Cancer Immunol Immunother. 2014 Mar; 63(3):297-303.